Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA, Choi W, Cojocaru G, Fu W, Hsiue EH, Oke TF, Siegel N, Fong MH, Ladle B, Pratilas CA, Morris CD, Levin A, Rhee DS, Meyer CF, Tam AJ, Blosser R, Thompson ED, Suru A, McConkey D, Housseau F, Anders R, Pardoll DM, Llosa N.
Ligon JA, et al. Among authors: morris cd.
J Immunother Cancer. 2021 May;9(5):e001772. doi: 10.1136/jitc-2020-001772.
J Immunother Cancer. 2021.
PMID: 34021032
Free PMC article.